Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Hematologic Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Small Intestinal Neuroendocrine Tumor 1Papillomavirus Infections 1Pancreatic Adenocarcinoma 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma 1Leukemia 1Heart Failure 1HER2-positive Breast Cancer 1Cystic Fibrosis 1Cardiomyopathies 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Trastuzumab 33pertuzumab 18Docetaxel 16pyrotinib 15Paclitaxel 7Capecitabine 6tucatinib 5Carboplatin 5Ado-Trastuzumab Emtansine 4trastuzumab deruxtecan 3neratinib 3atezolizumab 2Protons 2Neoadjuvant Therapy 2Fulvestrant 2pegfilgrastim 1palbociclib 1margetuximab 1liposomal doxorubicin 1inavolisib 1exemestane 1envafolimab 1dalpiciclib 1Taxoids 1Metformin 1Leuprolide 1Letrozole 1Isovaleryl-CoA Dehydrogenase 1Injections 1Hospital Information Systems 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-positive Breast Cancer × Electronic Health Records × Clear all
NCT05769751 2023-08-16

A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer

Daiichi Sankyo

Completed
865 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡